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Nucleotides released by apoptotic 
cells act as a find-me signal  
to promote phagocytic clearance
Elliott et al., Nature 2009; 461: 282–286; doi:10.1038/nature08296
The importance of apoptosis and removal of apoptotic bodies 
for normal renal development as well as for renal diseases is well 
recognized. The process of phagocytic removal of apoptotic cells 
occurs efficiently in vivo such that even in tissues with significant 
apoptosis, very few apoptotic cells are detectable. This is thought 
to be due to the release of ‘find-me’ signals by apoptotic cells that 
recruit motile phagocytes such as monocytes, macrophages, and 
dendritic cells, leading to the prompt clearance of the dying cells. 
Recently, Elliott et al. have identified extracellular nucleotides as a 
critical apoptotic-cell find-me signal demonstrating the caspase-
dependent release of ATP and UTP during the early stages of apop-
tosis by primary thymocytes and cell lines. Removal of ATP and 
UTP abrogated the ability of apoptotic-cell supernatants to recruit 
monocytes in vitro and in vivo. The authors identified the ATP/
UTP receptor P2Y2 as a critical sensor of nucleotides released by 
apoptotic cells, using RNA interference-mediated depletion stud-
ies in monocytes and macrophages from P2Y2-null mice. Further, 
clearance of apoptotic thymocytes was significantly impaired by 
either depletion of nucleotides or interference with P2Y receptor 
function (by pharmacological inhibition or in P2Y2–/– mice). These 
results identify nucleotides as a critical find-me cue released by 
apoptotic cells to promote P2Y2-dependent recruitment of phago-
cytes, and they provide evidence for a clear relationship between a 
find-me signal and efficient corpse clearance in vivo.
These findings will allow pharmacological manipulation 
with existing agents. For example, delayed removal of apop-
totic bodies is implicated in the pathobiology of systemic lupus 
and may play a role in other autoimmune diseases as well. 
Finally, changes in the rate of apoptosis of renal cells such as 
podocytes, tubular epithelial cells, and endothelial cells are 
considered the major reason for progression of glomerular and 
tubulointerstitial disease. Now, changes in removal of apoptotic 
cells as potential factors in disease progression are amenable to 
experimental manipulation. Such manipulation may apply to 
kidney cells and could be extrapolated to removal of apoptotic 
leukocytes in end-stage renal disease patients and thereby to 
alterations in the immune response of these patients.
Detlef Schlöndorff
Regulation of renal function  
by circadian clock
Gumz et al., J Clin Invest 2009; 119: 2423–2434; doi:10.1172/JCI36908
Zuber et al., Proc Natl Acad Sci USA 2009; 106: 16523–16528; doi:10.1073/
pnas.0904890106
Many physiological functions are modulated by circadian 
rhythms. The mammalian circadian timing system is driven by 
a central pacemaker located in the hypothalamic suprachias-
matic nucleus, which functions in a self-sustained fashion but 
is also reset each day by exposure to environmental synchroniz-
ers, mainly the light–dark cycle. In the kidney, the most obvious 
manifestation of a circadian rhythm is the marked difference 
in urine volume between day and night. However, the urinary 
excretion of many solutes, including sodium, potassium, and 
urea, also follows a circadian oscillating pattern. Although renal 
excretion rhythms are synchronized with circadian rhythms of 
activity and feeding, they persist under experimental conditions 
in which external factors are kept constant or are manipulated in 
a non-circadian manner. These results suggest that, in addition to 
the external circadian stimuli (hormones, food, and so on), renal 
function oscillations are also controlled by a self-sustained intrin-
sic renal clock. Work from two different laboratories further sup-
ports this view. Using an inner medullary collecting duct cell line 
and microarray analysis, Gumz et al. had previously found that 
the transcript induced to the greatest extent by aldosterone was 
the circadian clock gene Per1. Recently, they reported that Per1 
was induced by aldosterone in vivo (Figure) and that its RNA 
silencing dramatically decreased expression of mRNA encod-
ing αENaC in the presence or absence of aldosterone. Moreover, 
αENaC levels were significantly reduced in the inner medullas of 
mice with targeted disruption of Per1, implicating this gene in the 
regulation of renal αENaC. Interestingly, renal αENaC-encoding 
mRNA was expressed in a circadian pattern, and this pattern was 
dramatically altered in mice lacking Per1. In another study, Zuber 
et al. microdissected mouse distal convoluted tubules, connecting 
tubules, and cortical collecting ducts and performed temporal 
expression analysis. They found marked circadian rhythmicity 
in the expression of a large number of genes crucially involved 
in many homeostatic functions of the kidney. Moreover, all these 
nephron segments displayed oscillations in the expression of sev-
eral circadian clock genes (clock, bma11, npas2, per, cry, nr1d1) 
and clock-controlled transcriptional factors (dbp, hlf, and tef). 
Finally, the authors found that mice with clock deleted and mice 
devoid of dbp, hlf, and tef (triple knockout) exhibited significant 
changes in renal expression of several important regulators of 
water or sodium balance (including the vasopressin V2 receptor, 
aquaporin-2, aquaporin-4, and αENaC) and that loss of clock 
Paraffin-embedded sections from thymuses of wild-type and P2Y2
–/– 
mice treated with dexamethasone (Dex) for 6 hours (brown, Apostain; 
blue, hematoxylin). 
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leads to partial diabetes insipidus and abnormal sodium excre-
tion. These studies highlight the critical role of the circadian clock 
in control of sodium balance and renal function.
Qais Al-Awqati
Effects of losartan independent  
of its AT1 receptor blockade
Kappert et al., Hypertension 2009; 54: 738–743; doi:10.1161/
HYPERTENSIONAHA.109.132886
Fortuño et al., Hypertension 2009; 54: 744–750; doi:10.1161/
HYPERTENSIONAHA.109.129353
Blockade of the renin–angiotensin system has emerged as one of 
the most promising therapies for several cardiovascular, metabolic, 
and kidney diseases. These therapies are not only effective but also 
intellectually elegant, as much is understood about the system. It 
is becoming apparent, however, that much remains unknown and 
that surprises abound. For example, losartan is metabolized by 
the cytochrome P450 pathway and exerts its angiotensin type 1 
receptor (AT1R)-blocking effect by its main metabolite, labeled 
EXP3174. Hepatic metabolism of losartan also generates a com-
pound known as EXP3179, which has no affinity for AT1R but 
appears to exert a variety of other effects. It was found several 
years ago that EXP3179 was capable of inhibiting endothelial 
cyclooxygenase-2 and, more recently, that it could activate peroxi-
some proliferator-activated receptor γ (PPARγ). This latter effect 
is of substantial interest since the thiazolidinediones, which are 
PPARγ activators, increase insulin sensitivity. Another pathway of 
great interest in cardiovascular and renal pharmacology is the gen-
eration of superoxide anion (O2•–) by NADPH oxidases, as oxida-
tive stress induced by a variety of reactive oxygen species, including 
O2•–, is increased in arterial hypertension. Two recent publications 
present tantalizing evidence that EXP3179 may be involved in the 
regulations of these pathways in vivo. Kappert et al. examined 
whether chronic treatment with losartan may result in concentra-
tions of EXP3179 that activate PPARγ. They found that expression 
of PPARγ target genes (CD36 and ABC transporter G1) in mono-
cytes from losartan-treated patients was significantly upregulated 
in comparison with appropriate control patients. Fortuño et al. 
investigated the effect of losartan and its metabolites on NADPH 
oxidase activity in human phagocytic and endothelial cells. They 
found that EXP3179, but neither losartan nor EXP3174, inhibited 
phorbol myristate acetate and insulin-stimulated NADPH oxidase 
activity. Further, they found that phagocytic NADPH oxidase 
activity was lower in losartan-treated hypertensive patients than 
in untreated patients. These studies suggest that treatment with 
losartan may result in PPARγ activation and reduction of oxidative 
stress due to effects of its metabolite EXP3179.
Juan Oliver
Mitochondrial tubulopathy  
in tenofovir disoproxil  
fumarate-treated rats
Lebrecht et al., J Acquir Immune Defic Syndr 2009; 51: 258–263; doi:10.1097/
QAI.0b013e3181a666eb
Tenofovir is a nucleotide reverse transcriptase inhibitor used in 
the treatment of HIV infection. The literature has several reports 
of acute kidney injury as well as proximal renal tubular dysfunc-
tion and Fanconi’s syndrome associated with the use of tenofo-
vir in persons with HIV. As very few cases have been biopsied, 
limited information exists regarding the potential mechanism for 
the acute tubular necrosis described. Many nucleoside/nucleotide 
reverse transcriptase inhibitors have a clinically relevant affinity for 
mitochondrial polymerase enzymes greater than that of tenofovir. 
However, it is hypothesized that high intracellular concentrations 
of tenofovir in tubular cells counterbalance this lower affinity. Leb-
recht et al. examined in rats the histologic changes associated with 
prolonged doses of tenofovir at levels two times greater than those 
used in humans, focusing on the mitochondrial structure and cop-
ies of mitochondrial DNA. Three groups of eight 5-week-old rats 
were gavaged with 100 mg/kg per day of tenofovir, 100 mg/kg per 
day of didanosine, or vehicle. All animals were killed after 8 weeks 
of treatment. Rats receiving didanosine grew at the same rate as 
those receiving water. Rats receiving tenofovir had a terminal body 
weight that was 13% lower than that of controls. In rats receiving 
tenofovir, small droplets of intracellular lipids were found in some 
tubular cells, and the proximal tubular cells showed enlarged mito-
chondria featuring a disrupted crystal architecture. Among all rats, 
the tubular diameters were inversely correlated with the weights of 
the animals, with the tenofovir animals demonstrating the great-
est tubular diameters. Also, the tenofovir animals had the fewest 
copies of mitochondrial DNA in isolates normalized for body 
weight and proximal tubular diameter. Finally, histochemistry 
demonstrated low tubular cytochrome c oxidase and nicotinamide 
adenine dinucleotide dehydrogenase activities.
This study demonstrates significant tubular changes in rats 
receiving high doses of tenofovir. If mitochondrial toxicity is 
the mechanism by which AKI occurs in humans, then presum-
ably dose-ranging studies can be done to attempt to understand 
whether this is an idiosyncratic toxicity or a dose-related risk. 
Although the relatively similar changes among all rats receiving 
tenofovir somewhat support the latter, this would need to be 
more definitively explored in dedicated studies to determine how 
best to limit the risk in humans.
Lynda Szczech 
 Per1 is induced by aldosterone in vivo.
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